A novel treatment for Riehl's melanosis targeting both dermal melanin and vessels.
Riehl's melanosis
diffractive lens array
picosecond laser
pulsed dye laser
Journal
Photodermatology, photoimmunology & photomedicine
ISSN: 1600-0781
Titre abrégé: Photodermatol Photoimmunol Photomed
Pays: England
ID NLM: 9013641
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
24
07
2023
received:
18
06
2023
accepted:
08
08
2023
medline:
16
11
2023
pubmed:
24
8
2023
entrez:
24
8
2023
Statut:
ppublish
Résumé
Riehl's melanosis is a difficult-to-treat condition characterized by persisting dermal hyperpigmentation. This study aimed to evaluate the efficacy of a histology-specific targeted therapy for Riehl's melanosis. Skin biopsy samples of Riehl's melanosis were assessed to identify histology-specific targets for treatment. Subsequently, the efficacy of a combination involving a fractional picosecond laser and a pulsed dye laser (PDL) targeting the dermal melanin and vessels, respectively, was evaluated. Clinical improvement was assessed using the dermal pigmentation area and severity index (DPASI). The treatment outcomes were compared to those of a control, in this case a single laser treatment solely targeting pigmentation. Histological and immunohistochemical analyses identified dermal melanin pigment and dilated vessels as treatment targets for Riehl's melanosis. The combined treatment of the fractional picosecond laser and PDL showed a significant reduction of the DPASI scores, which was significantly better than the control group. Patients who underwent the combined laser treatment indicated high levels of satisfaction with no adverse events except of transient erythema and oedema. The combined treatment of a fractional picosecond laser and a PDL was more effective for Riehl's melanosis compared to single laser treatment. The treatment targets both dermal pigmentation and dilated vessels, offering promising results for those working to manage Riehl's melanosis.
Sections du résumé
BACKGROUND/PURPOSE
OBJECTIVE
Riehl's melanosis is a difficult-to-treat condition characterized by persisting dermal hyperpigmentation. This study aimed to evaluate the efficacy of a histology-specific targeted therapy for Riehl's melanosis.
METHODS
METHODS
Skin biopsy samples of Riehl's melanosis were assessed to identify histology-specific targets for treatment. Subsequently, the efficacy of a combination involving a fractional picosecond laser and a pulsed dye laser (PDL) targeting the dermal melanin and vessels, respectively, was evaluated. Clinical improvement was assessed using the dermal pigmentation area and severity index (DPASI). The treatment outcomes were compared to those of a control, in this case a single laser treatment solely targeting pigmentation.
RESULTS
RESULTS
Histological and immunohistochemical analyses identified dermal melanin pigment and dilated vessels as treatment targets for Riehl's melanosis. The combined treatment of the fractional picosecond laser and PDL showed a significant reduction of the DPASI scores, which was significantly better than the control group. Patients who underwent the combined laser treatment indicated high levels of satisfaction with no adverse events except of transient erythema and oedema.
CONCLUSION
CONCLUSIONS
The combined treatment of a fractional picosecond laser and a PDL was more effective for Riehl's melanosis compared to single laser treatment. The treatment targets both dermal pigmentation and dilated vessels, offering promising results for those working to manage Riehl's melanosis.
Substances chimiques
Melanins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
613-619Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Park JY, Kim Y, Lee ES, Park KC, Kang H. Acquired bilateral melanosis of the neck in perimenopausal women. Br J Dermatol. 2012;166(3):662-665.
Kwon HH, Ohn J, Suh DH, et al. A pilot study for triple combination therapy with a low-fluence 1064 nm Q-switched Nd:YAG laser, hydroquinone cream and oral tranexamic acid for recalcitrant Riehl's melanosis. J Dermatolog Treat. 2017;28(2):155-159.
Cho MY, Roh MR. Successful treatment of Riehl's melanosis with mid-fluence Q-switched Nd:YAG 1064-nm laser. Lasers Surg Med. 2020;52(8):753-760.
Vinay K, Bishnoi A, Parsad D, Saikia UN, Sendhil KM. Dermatoscopic evaluation and histopathological correlation of acquired dermal macular hyperpigmentation. Int J Dermatol. 2017;56(12):1395-1399.
Kim SM, Hwang S, Almurayshid A, Park MY, Oh SH. Non-ablative 1927 nm fractional thulium fiber laser: new, promising treatment modality for Riehl's melanosis. Lasers Surg Med. 2021;53(5):640-646.
Wang L, Xu AE. Four views of Riehl's melanosis: clinical appearance, dermoscopy, confocal microscopy and histopathology. J Eur Acad Dermatol Venereol. 2014;28(9):1199-1206.
Yim JH, Kang I-H, Shin MK, Lee M-H. Differences among dermoscopic findings in Riehl's melanosis of the cheek and neck. Ann Dermatol. 2019;31(4):460-463.
Kumaran M, Dabas G, Vinay K, Parsad D. Reliability assessment and validation of the dermal pigmentation area and severity index: a new scoring method for acquired dermal macular hyperpigmentation. J Eur Acad Dermatol Venereol. 2019;33(7):1386-1392.
Sriwiriyanont P, Ohuchi A, Hachiya A, Visscher MO, Boissy RE. Interaction between stem cell factor and endothelin-1: effects on melanogenesis in human skin xenografts. Lab Invest. 2006;86(11):1115-1125.
Hasegawa K, Fujiwara R, Sato K, et al. Increased blood flow and vasculature in solar lentigo. J Dermatol. 2016;43(10):1209-1213.
Kim M, Shibata T, Kwon S, Park TJ, Kang HY. Ultraviolet-irradiated endothelial cells secrete stem cell factor and induce epidermal pigmentation. Sci Rep. 2018;8(1):4235.
Woo YR, Park HE, Jeong S-W, Park HJ. Melanogenic properties and expression profiles of melanogenic paracrine molecules in Riehl's melanosis. Int J Mol Sci. 2020;21(5):1695.
Passeron T, Fontas E, Kang HY, Bahadoran P, Lacour J-P, Ortonne J-P. Melasma treatment with pulsed-dye laser and triple combination cream: a prospective, randomized, single-blind, split-face study. Arch Dermatol. 2011;147(9):1106-1108.
Kang HY, Ortonne JP. What should be considered in treatment of melasma. Ann Dermatol. 2010;22(4):373-378.
Forbat E, Al-Niaimi F. Nonvascular uses of pulsed dye laser in clinical dermatology. J Cosmet Dermatol. 2019;18(5):1186-1201.
Smit J, Bauland C, Wijnberg D, Spauwen P. Pulsed dye laser treatment, a review of indications and outcome based on published trials. Br J Plast Surg. 2005;58(7):981-987.
Kang H. Melasma and aspects of pigmentary disorders in Asians. Ann Dermatol Venereol. 2012;139(S4):S114-S147.
Ghaninejhadi H, Ehsani A, Edrisi L, Gholamali F, Akbari Z, Noormohammadpour P. Solar lentigines: evaluating pulsed dye laser as an effective treatment option. J Lasers Med Sci. 2013;4(1):33-38.
Moody BR, McCarthy JE, Hruza GJ. Collagen remodeling after 585-nm pulsed dye laser irradiation: an ultrasonographic analysis. Dermatol Surg. 2003;29(10):997-1000.
Kauvar AN, Rosen N, Khrom T. A newly modified 595-nm pulsed dye laser with compression handpiece for the treatment of photodamaged skin. Laser Surg Med. 2006;38(9):808-813.
Weiss RA, McDaniel DH, Weiss MA, Mahoney AM, Beasley KL, Halvorson CR. Safety and efficacy of a novel diffractive lens array using a picosecond 755 nm alexandrite laser for treatment of wrinkles. Lasers Surg Med. 2017;49(1):40-44.
Haimovic A, Brauer JA, Cindy Bae YS, Geronemus RG. Safety of a picosecond laser with diffractive lens array in the treatment of Fitzpatrick skin types IV to VI: a retrospective review. J Am Acad Dermatol. 2016;74(5):931-936.